Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 27-37

  LaRusso, Jennifer ^a   Waldman, Scott A ^a   Kraft, Walter K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; NABILONE; NEUROTRANSMITTER; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PEMETREXED; PLACEBO; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANESTHETIC RECOVERY; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRADYCARDIA; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PACKAGING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTRITIS; HICCUP; HUMAN; ISOTOPE LABELING; LOW DRUG DOSE; MENSTRUATION DISORDER; MORNING DOSAGE; MOTION SICKNESS; MULTIPLE CYCLE TREATMENT; NAUSEA; PATHOPHYSIOLOGY; POSTANESTHESIA CARE; POSTMARKETING SURVEILLANCE; POSTOPERATIVE NAUSEA AND VOMITING; PROTEINURIA; RADIOACTIVITY; RECOMMENDED DRUG DOSE; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 38349071618     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.27     Document Type: Article

References (64)

1. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin. Emerg. Drugs 11(1), 137-151 (2006).
2. Navari RM. Pathogenesis-based treatment of chemotherapy induced nausea and vomiting: two new agents. J. Support. Oncol. 1, 89-103 (2003).
3. Kris MG. Why do we need another anti-emetic? J. Clin. Oncol. 21, 4077-4080 (2003).
4. ASPAN'S evidence-based clinical practice guideline for the prevention and/or management of PONV/PDNV. J. Perianesth. Nurs. 21, 230-250 (2006).
5. Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J. Pain Palliat. Care Pharmacother. 19, 31-39 (2005).
6. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64, 777-794 (2004).
7. Carpenter DO. Neural mechanisms of emesis. Can. J. Physiol. Pharmacol. 68, 230 (1990)
8. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann. Pharmacother. 39, 77-85 (2005).
9. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev. Anticancer Ther. 4, 715-724 (2004).
10. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J. Support. Oncol. 5, 5-12 (2007).
11. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting: providing a basis for therapeutic progress. Oncology 18, 9-14 (2004).
12. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J. Clin. Oncol. 2, 1170-1176 (1984).
13. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support. Care Cancer 13, 80-84 (2005).
14. Kris MG, Hesketh PJ, Somerfield MR et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol. 24, 2932-2947 (2006).
15. Apfel CC, Korttila K, Abdalla M et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N. Engl. J. Med. 350, 2441-2451 (2004).
16. Carroll NV, Miederhoff P, Cox FM, Hirsch JD. Postoperative nausea and vomiting after discharge from outpatient surgery centers. Anesth. Analg. 80, 903-909 (1995).
17. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth. Analg. 102, 1884-1898 (2006).
18. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database of Syst. Rev. 3, CD004125 (2006).
19. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonist be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23, 1289-1294 (2005).
20. 3 receptor antagonists. Ann. Pharmacother. 37, 1276-1286 (2003).
21. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14, 1570-1577 (2003).
22. 3-receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98, 2473-2482 (2003).
23. Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17, 1441-1449 (2006).
24. Olver IN. Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting. Int. J. Clin. Pract. 58, 201-206 (2004).
25. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry 63, 18-24 (2002).
26. Emend (aprepitant), product information. Merck, White House Station, NJ, USA (2006).
27. Majumdar AK, Howard L, Goldberg MR et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 46, 291-300 (2006).
28. Sanchez RI, Wang RW, Newton DJ. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab. Dispos. 32, 1287-1292 (2004).
29. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J. Clin. Pharmacol. 44, 215-223 (2004).
30. Feuring M, Lee Y, Orlowski LH et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 43, 912-917 (2003).
31. Bergman AJ, Marbury T, Fosbinder T et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin. Pharmacokinet. 44, 637-647 (2005).
32. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr. Blood Cancer 45, 857-860 (2005).
33. Bergstrom M, Hargreaves RJ, Burns HD et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012 (2004).
34. McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. 74, 17-24 (2003).
35. Majumdar AK, McCrea JB, Panebianco DL et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther. 74, 150-156 (2003).
36. Depré M, Van Hecken A, Oeyen M et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur. J. Clin. Pharmacol. 61, 341-346 (2005).
37. Blum RA, Majumdar AK, McCrea JB et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. Ther. 25, 1407-1419 (2003).
38. Li SX, Pequignot E, Panebianco D et al. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. J. Clin. Pharmacol. 46(7), 792-801 (2006).
39. Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr. Med. Res. Opin. 21(4), 595-601 (2005).
40. Loos WJ, de Wit R, Freedman SJ et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother. Pharmacol. 59, 407-412 (2007).
41. Nygren P, Hande K, Petty KJ et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother. Pharmacol. 55, 609-616 (2005).
42. Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer 37, 835-842 (2001).
43. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer 94, 3032-3041 (2002).
44. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron a dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19, 1759-1767 (2001).
45. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N. Engl. J. Med. 340, 190-195 (1999).
46. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer 97, 2290-2300 (2003).
47. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 97, 3090-3098 (2003).
48. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J. Clin. Oncol. 21, 4112-4119 (2003).
49. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol. 17, 1000-1006 (2006).
50. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin Oncol. 21, 4105-4111 (2003).
51. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23, 2822-2830 (2005).
52. Gan TJ, Apfel CC, Kovac A et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth. Analg. 104, 1082-1089 (2007).
53. Diemunsch P, Gan TJ, Philip BK et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery. Br. J. Anaesth. 99, 202-211 (2007).
54. Lasseter KC, Gambale J, Jin B et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol. 47, 834-840 (2007).
55. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 10, 23-31 (2007).
56. Hesketh PJ, Grunberg SM, Herrstedt J et al. Combined data from two Phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support. Care Cancer 14, 354-360 (2006).
57. Koren G, Levichek Z. The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. Am. J. Obstet. Gynecol. 186(5 Suppl.), S248-S252 (2002).
58. Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst. Rev. 4, CD000145 (2003).
59. Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.J. Urol. 176(6 Pt 1), 2535-2540 (2006).
60. Keller M, Montgomery S, Ball W et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216-223 (2006).
61. Sindrup SH, Graf A, Sfikas N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur. J. Pain. 10, 567-571 (2006).
62. Goldstein DJ, Offen WW, Klein EG et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21, 102-106 (2001).
63. Hernandez J, Lackner A, Aye P et al. Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. Infect. Immun. 75, 1137-1143 (2007).
64. Boot JD, de Haas S, Tarasevych S et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am. J. Respir. Crit. Care Med. 175, 450-457 (2007).